Drug Trial Radar · NCT05630768
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Jan 3, 2023
Primary completion
Jul 23, 2025
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
Conditions
- Postmenopausal Osteoporosis
Interventions
Risedronate Sodium 35 MG [Actonel]Drug
Risendronate Sodium Tab. 35mg, orally, once weekly
Calcium Vitamin D combinationDrug
orally, once daily for concomitant drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.